Recent developments of cathepsin inhibitors and their selectivity

Bibliography

• TRABANDT A, GAY RE, FASSBENDER, GAY S: Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritic Rheum. (1991) 34:1444–1451.
   PubMedGoogle Scholar
• BRESNIHAN B: Pathogenesis of joint damage in rheumatoid arthritis.' Rheumatol (1999) 26:717–719.
   Google Scholar
• HANSEN T, PETROW PK, GAUMANN et al.: Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium.f. Rheumatol (2000) 27(4):859–865.
   Google Scholar
• SCHOTTE P, SCHAUVLIEGE R, S, BEYAERT R: The cathepsin inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide.f Biol. Chem. (2001) 276(24):21153–21157.
   Google Scholar
• TSUGE H, NISHIMURA T, TADA Yet.: Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem. Biophys. Res. Commun. (1999) 266:411–416.
   Google Scholar
• XIA L, KILB J, WEX H et al.: Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. (1999) 380:679–687.
   PubMed Web of Science ®Google Scholar
• PERCIVAL MD, OUELLET M, CAMPAGNOLO C, CLAVEAU D, LI C: Inhibition of cathepsin K by nitric oxide donors: evidence for formation of mixed disulfides and a sulfenic acid. Biochemistry (1999) 38:13574–13583.
   PubMed Web of Science ®Google Scholar
• LALONDE JM, ZHAO B, SMITH WW et al.: Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites. Med. Chem. (1998) 41(23):4567–4576.
   Google Scholar
• JAHKOLA T, TOIVONEN T, SMITTEN, VIRTANEN I, WASENIUS VM, BLOMQVIST C: Cathepsin D, urokinase plasminogen activator and type-1 plasminoben activator inhibitor in early breast cancer: an immunochemical study of prognostic value and relations to tenascin-C and other factors. Br. Cancer (1999) 80(11 2):167–174.
   Google Scholar
• POHL J, ZAORAL M, JINDRA A, R. J, KOSTKA V: Purification pepsins and cathepsin D by affinity chromatography on sepharose 4B with an immobilized synthetic inhibitor. Anal. Biochem. (1984) 139:265–271.
   PubMedGoogle Scholar
• TSUKUBA T, OKAMOTO K, YASUDA Y, MORIKAWA W, NAKANISHI H, YAMAMOTO K: New functional aspects od cathepsin D and cathepsin E. Mol Cells (2000) 10(6):601–611.
   PubMed Web of Science ®Google Scholar
• STROJAN P, BUDIHNA M, SMID L, VRHOVEC I, SKRK J: Urokinase-type plasminogen activator, plasminogen activator inhibitor Type 1 and cathepsin D:analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res. (2000) 20:3975–3982.
   PubMedGoogle Scholar
• STROJAN P: Cathepsins and their endogenous inhibitors in clinical oncology. Radial Oncol. (1996) 30:120–133.
   Google Scholar
• SCOTT FL, HIRST CE, SUN J, BIRD CH, BOTTOMLEY SP, BIRD PI: The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G. Blood (1999) 93(6):2089–2097.
   PubMedGoogle Scholar
• HIRAIWA M: Cathepsin A/protective protein: anusual lysosomal multifunctional protein. Cell. Ma Life ScL (1999) 56(11):894–907.
   PubMedGoogle Scholar
• GUAY J, FALGUEYRET JP, DUCRET A, PERCIVAL MD, MANCINI JA: Potency and selectivity of inhibition of cathepsin K, and S by their respective properties. Ear: Biochem. (2000) 267:6311–6318.
   PubMedGoogle Scholar
• YAMASHITA DS, DODDS RA: Cathepsin and the design of inhibitors of cathepsin K. Curt. Pharm. Design (2000) 6(1):1–24.
   PubMedGoogle Scholar
• HALL A, HAKANSSON K, MANSON RW, GRUBB A, ABRAHAMSON M: Structural basis for the biological specificity of cystatin C. J. Biol. Chem. (1995) 270:5115–5121.
   PubMed Web of Science ®Google Scholar
• ESTRADA S, PAVLOVA A, BJORK I: Thecontribution of N-terminal region of cystatin A(Stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B and cathepsin L. Biochemistry (1999) 38:7339–7345.
   PubMedGoogle Scholar
• PAVLOVA A, KRUPA JC, MORT JS, ABRAHAMSON M, BJORK I: Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of his110. FEBS Lett. (2000) 487(2):156–160.
   Google Scholar
• ABRAHAMSON M, MASON RW, HANSSON H, BUTTLE DJ, GRUBB A,OHLSSON K: Human cystatin C: role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leukocyte elastase. Biochem. (1991) 273:621–626.
   Google Scholar
• RICCIO M, DI GIAIMO R, PIANETTI S, PALMIERI PP, MELLI M, SANTI S: Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM 1). Exp. Cell Res. (2001) 262(2):84–94.
   PubMedGoogle Scholar
• LAH TT, CLIFFORD JL, HELMER KM et al.: Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. Biochim. Biophys. Acta (1989) 993:63–73.
   PubMedGoogle Scholar
• SLOANA BE MOIN K, KREPELA E, ROZHIN J: Cathepsin B and its endogenous inhibitors: the role in tumour malignancy. Cancer Metast. Rev (1991) 9:333–352.
   Google Scholar
• CHAMBERS AF, TUCK AB: Ras-responsive genes and tumour metastasis. Grit. Rev Omni (1993) 9:95–114.
   Google Scholar
• ISHIURA S, HANADA K, TAMAI M, KASHIWAGI K, SUGITA H: The effect of an in vivo-injected thiol protease inhibitor, E-64-c, on the calcium-induced degeneration of myofilaments. Biochem. (1981) 90(5):1557–1560.
   Google Scholar
• TATUNUMA N, MURATA E, KAKEGAWA H et al.: Structure based development of novel specific inhibitors for cathepsin L and cathepsin S M vitro and in vivo. FEBS Lett. (1999) 458:6–10
   PubMedGoogle Scholar
• BARRET AJ, KEMBHAVI AA, BROWN MA et al.: L-trans-epoxysuccinyl-leucylamido -guanidino) butane [E64] and its analogues as inhibitors of cysteine proteinases including cathepsin S, B, H and. Biochem. (1982) 201:189–198.
   Google Scholar
• TOWATARI T, NIKAWA T, MURATA M et al.: Novel epoxysuccinyl peptides: a selective inhibitor of cathepsin B, M viva FEBS Lett. (1991) 280:311–315.
   Google Scholar
• MATSUNAGA Y, SAIBARA T, KIDO H, KATUNUMA N: Participation of cathepsin B in processing of antigen presentation to MHC class II. FEBS Lett (1993) 324:325–330.
   PubMedGoogle Scholar
• FUSETANI N, FUJITA M, NAKAO Y, MATSUNAGA S: Tokaramide A, a new cathepsin B inhibitor from marine sponge Theonella aff. mirabilis. Bioorg. Med. Chem. Lett. (1999) 9:3397–3402.
   PubMedGoogle Scholar
• Weislow OS, Kiser R, Fine DL et al.: New-soluble formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Nat. Cancer Inst. (1989) 81:577–586.
   PubMed Web of Science ®Google Scholar
• BEATTY K, BEITH J, TRAVIS J: Kinetics of association of serine proteinases with native oxidized al-proteinase inhibitor and al-antichymotrypsin. Biol. Chem. (1980) 255:3931–3934.
   Google Scholar
• TRAVIS J: Structure, function and control of neutrophil proteinases. Am. Med. (1988) 84:37–42.
   PubMedGoogle Scholar
• POTEMPA J, KORZUS E, TRAVIS J: The serpin superfamily of proteinase inhibitors: structure, function and regulation. Biol. Chem. (1994) 269:15957–15960.
   Google Scholar
• TRAVIS J, POTEMPA J, BANGALORE N, KURDOWSKA A: Multiple functions of neutrophil proteinases and their inhibitor complexes. In: Biochemistry of pulmonary emphysema. Grassi C, Travis J, Casali L, Luisetti, M (Eds.), Springer-Verlag, London (1992):71–79.
   Google Scholar
• DURANTON J, BOUDIER C, D, MELLET P, BEITH JG: DNA strongly impairsthe inhibition of cathepsin G by _1-antichymotrypsin and _1-proteinase inhibitor. J. Biol. Chem. (2000) 275(6):3787–3792.
   PubMedGoogle Scholar
• DURANTON J, ADAM C, BEITH JG: Kinetic mechanism of the inhibition of cathepsin G by _1-antichymotrypsin and _1-proteinase inhibitor. Biochemistry (1998) 37:11239–11245.
   PubMedGoogle Scholar
• BANIA J, STACHOWIAK D, A: Primary structure and properties of the cathepsin G/chymotrypsin inhibitor from the larval hemolymph of Apis melli feta. Eur: Biochem. (1999) 262:680–687.
   PubMedGoogle Scholar
• POLANOWSKI A, WILUSZ T, BLUM SM, ESCOUBAS P, SCHMIDT JO, TRAVIS J: Serine proteinase inhibitor profiles in the hemolymph of a wide range of insect species. Comp. Biochem. Physiol (1992) 102(B):757–760.
   Google Scholar
• KIM WM, KANG K: Enzymatic and molecular biochemical characterizations of human neutrophil elastases and a cathepsin G-like enzyme. Ma Cells. (2000) 10(5):498–504.
   Google Scholar